1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Enfermedades neurodegenerativas: mecanismos patogénicos

Enfermedades neurodegenerativas: mecanismos patogénicos

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • Blazquez, Cristina, Ruiz-Calvo, Andrea, Bajo-Graneras, Raquel, Baufreton, Jerome M., Resel, Eva, Varilh, Marjorie, Pagano Zottola AC, Mariani, Yamuna, Cannich, Astrid, Rodriguez-Navarro, Jose A., Marsicano, Giovanni, Galve-Roperh, Ismael, Bellocchio, Luigi, Guzman, Manuel.

    Inhibition of striatonigral autophagy as a link between cannabinoid intoxication and impairment of motor coordination

    ELIFE . 9: . Nº de citas: 5

    [doi:10.7554/eLife.56811]

  • Jimenez-Blasco, Daniel, Busquets-Garcia, Arnau, Hebert-Chatelain, Etienne, Serrat, Roman, Vicente-Gutierrez, Carlos, Ioannidou, Christina, Gomez-Sotres, Paula, Lopez-Fabuel, Irene, Resch-Beusher, Monica, Resel, Eva, Arnouil, Dorian, Saraswat, Dave, Varilh, Marjorie, Cannich, Astrid, Julio-Kalajzic, Francisca, Bonilla-Del Rio, Itziar, Almeida, Angeles, Puente, Nagore, Achicallende, Svein, Lopez-Rodriguez, Maria-Luz, Jolle, Charlotte, Deglon, Nicole, Pellerin, Luc, Josephine, Charlene, Bonvento, Gilles, Panatier, Aude, Lutz, Beat, Piazza, Pier-Vincenzo, Guzman, Manuel, Bellocchio, Luigi, Bouzier-Sore, Anne-Karine, Grandes, Pedro, Bolaños JP, Marsicano, Giovanni.

    Glucose metabolism links astroglial mitochondria to cannabinoid effects

    Nature . 583(7817): 603-608. Nº de citas: 126

    [doi:10.1038/s41586-020-2470-y]

  • Fernandez-Ruiz, Javier, Galve-Roperh, Ismael, Sagredo, Onintza, Guzman, Manuel.

    Possible therapeutic applications of cannabis in the neuropsychopharmacology field

    EUROPEAN NEUROPSYCHOPHARMACOLOGY . 36: 217-234. Nº de citas: 19

    [doi:10.1016/j.euroneuro.2020.01.013]

  • Moreno-Delgado D, Puigdellívol M, Moreno E, Rodríguez-Ruiz M, Botta J, Gasperini P, Chiarlone A, Howell LA, Scarselli M, Casadó V, Cortés A, Ferré S, Guzmán M, Lluís C, Alberch J, Canela EI, Ginés S, McCormick PJ.

    Modulation of dopamine D 1 receptors via histamine H 3 receptors is a novel therapeutic target for Huntington's disease.

    ELIFE . 9: . Nº de citas: 16

    [doi:10.7554/eLife.51093]

  • Navas-Olive, Andrea, Valero, Manuel, Jurado-Parras, Teresa, de Salas-Quiroga, Adan, Averkin, Robert G., Gambino, Giuditta, Cid, Elena, de la Prida, Liset M..

    Multimodal determinants of phase-locked dynamics across deep-superficial hippocampal sublayers during theta oscillations

    NATURE COMMUNICATIONS . 11(1): 2217-2217. Nº de citas: 31

    [doi:10.1038/s41467-020-15840-6]

  • de Salas-Quiroga, Adan, Garcia-Rincon, Daniel, Gomez-Dominguez, Daniel, Valero, Manuel, Simon-Sanchez, Samuel, Paraiso-Luna, Juan, Aguareles, Jose, Pujadas, Mitona, Muguruza, Carolina, Callado, Luis F., Lutz, Beat, Guzman, Manuel, de la Prida LM, Galve-Roperh, Ismael.

    Long-term hippocampal interneuronopathy drives sex-dimorphic spatial memory impairment induced by prenatal THC exposure

    NEUROPSYCHOPHARMACOLOGY . 45(5): 877-886. Nº de citas: 36

    [doi:10.1038/s41386-020-0621-3]

  • Abrams, Donald I., Guzman, Manuel.

    Can Cannabis Cure Cancer?

    JAMA Oncology . 6(3): 323-324. Nº de citas: 9

    [doi:10.1001/jamaoncol.2019.5983]

  • Ruiz-Calvo A, Bajo-Grañeras R, Maroto IB, Zian D, Grabner GF, García-Taboada E, Resel E, Zechner R, Zimmermann R, Ortega-Gutiérrez S, Galve-Roperh I, Bellocchio L, Guzmán M.

    Astroglial monoacylglycerol lipase controls mutant huntingtin-induced damage of striatal neurons.

    Neuropharmacology . 150: 134-144. Nº de citas: 11

    [doi:10.1016/j.neuropharm.2019.03.027]

  • Aguareles J, Paraíso-Luna J, Palomares B, Bajo-Grañeras R, Navarrete C, Ruiz-Calvo A, García-Rincón D, García-Taboada E, Guzmán M, Muñoz E, Galve-Roperh I.

    Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration.

    Translational Neurodegeneration . 8: 9-9. Nº de citas: 17

    [doi:10.1186/s40035-019-0148-x]

  • Blasco-Benito S, Moreno E, Seijo-Vila M, Tundidor I, Andradas C, Caffarel MM, Caro-Villalobos M, Urigüen L, Diez-Alarcia R, Moreno-Bueno G, Hernández L, Manso L, Homar-Ruano P, McCormick PJ, Bibic L, Bernadó-Morales C, Arribas J, Canals M, Casadó V, Canela EI, Guzmán M, Pérez-Gómez E, Sánchez C.

    Therapeutic targeting of HER2-CB 2 R heteromers in HER2-positive breast cancer.

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA . 116(9): 3863-3872. Nº de citas: 30

    [doi:10.1073/pnas.1815034116]

  • García-Rincón D, Díaz-Alonso J, Paraíso-Luna J, Ortega Z, Aguareles J, de Salas-Quiroga A, Jou C, de Prada I, Martínez-Cerdeño V, Aronica E, Guzmán M, Pérez-Jiménez MÁ, Galve-Roperh I.

    Contribution of Altered Endocannabinoid System to Overactive mTORC1 Signaling in Focal Cortical Dysplasia.

    FRONTIERS IN PHARMACOLOGY . 9: 1508-1508. Nº de citas: 6

    [doi:10.3389/fphar.2018.01508]

  • Roig-Puiggros S, Vigouroux RJ, Beckman D, Bocai NI, Chiou B, Davimes J, Gomez G, Grassi S, Hoque A, Karikari TK, Kiffer F, Lopez M, Lunghi G, Mazengenya P, Meier S, Olguín-Albuerne M, Oliveira MM, Paraíso-Luna J, Pradhan J, Radiske A, Ramos-Hryb AB, Ribeiro MC, Schellino R, Selles MC, Singh S, Theotokis P, Chédotal A.

    Construction and reconstruction of brain circuits: normal and pathological axon guidance.

    JOURNAL OF NEUROCHEMISTRY . 153(1): 10-32. Nº de citas: 10

    [doi:10.1111/jnc.14900]

  • Sagredo O, Palazuelos J, Gutierrez-Rodriguez A, Satta V, Galve-Roperh I, Martínez-Orgado J.

    Cannabinoid signalling in the immature brain: Encephalopathies and neurodevelopmental disorders.

    BIOCHEMICAL PHARMACOLOGY . 157: 85-96. Nº de citas: 9

    [doi:10.1016/j.bcp.2018.08.014]

  • Blasco-Benito S, Seijo-Vila M, Caro-Villalobos M, Tundidor I, Andradas C, García-Taboada E, Wade J, Smith S, Guzmán M, Pérez-Gómez E, Gordon M, Sánchez C.

    Appraising the entourage effect: Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer.

    BIOCHEMICAL PHARMACOLOGY . 157: 285-293.

    [doi:10.1016/j.bcp.2018.06.025]

  • Guzmán M.

    Cannabis for the Management of Cancer Symptoms: THC Version 2.0?

    Cannabis And Cannabinoid Research . 3(1): 117-119.

    [doi:10.1089/can.2018.0009]

  • Moreno E, Chiarlone A, Medrano M, Puigdellívol M, Bibic L, Howell LA, Resel E, Puente N, Casarejos MJ, Perucho J, Botta J, Suelves N, Ciruela F, Ginés S, Galve-Roperh I, Casadó V, Grandes P, Lutz B, Monory K, Canela EI, Lluís C, McCormick PJ, Guzmán M.

    Singular Location and Signaling Profile of Adenosine A 2A -Cannabinoid CB 1 Receptor Heteromers in the Dorsal Striatum.

    NEUROPSYCHOPHARMACOLOGY . 43(5): 964-977.

    [doi:10.1038/npp.2017.12]

  • Ruiz-Calvo A, Maroto IB, Bajo-Grañeras R, Chiarlone A, Gaudioso Á, Ferrero JJ, Resel E, Sánchez-Prieto J, Rodríguez-Navarro JA, Marsicano G, Galve-Roperh I, Bellocchio L, Guzmán M.

    Pathway-Specific Control of Striatal Neuron Vulnerability by Corticostriatal Cannabinoid CB1 Receptors.

    CEREBRAL CORTEX . 28(1): 307-322. Nº de citas: 19

    [doi:10.1093/cercor/bhx285]

  • Mateo Y, Johnson KA, Covey DP, Atwood BK, Wang HL, Zhang S, Gildish I, Cachope R, Bellocchio L, Guzmán M, Morales M, Cheer JF, Lovinger DM.

    Endocannabinoid Actions on Cortical Terminals Orchestrate Local Modulation of Dopamine Release in the Nucleus Accumbens.

    Neuron . 96(5): . Nº de citas: 61

    [doi:10.1016/j.neuron.2017.11.012]